[go: up one dir, main page]

HK33695A - Leukaemia inhibitory factor - Google Patents

Leukaemia inhibitory factor Download PDF

Info

Publication number
HK33695A
HK33695A HK33695A HK33695A HK33695A HK 33695 A HK33695 A HK 33695A HK 33695 A HK33695 A HK 33695A HK 33695 A HK33695 A HK 33695A HK 33695 A HK33695 A HK 33695A
Authority
HK
Hong Kong
Prior art keywords
lif
polypeptide
cells
murine
amino acid
Prior art date
Application number
HK33695A
Other languages
German (de)
English (en)
French (fr)
Inventor
David Paul Gearing
Nicholas Martin Gough
Douglas James Hilton
Julie Ann King
Donald Metcalf
Original Assignee
Amrad Corporation Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amrad Corporation Limited filed Critical Amrad Corporation Limited
Publication of HK33695A publication Critical patent/HK33695A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5415—Leukaemia inhibitory factor [LIF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/14—Fungi; Culture media therefor
    • C12N1/16—Yeasts; Culture media therefor
    • C12N1/18—Baker's yeast; Brewer's yeast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/23—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a GST-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/95—Fusion polypeptide containing a motif/fusion for degradation (ubiquitin fusions, PEST sequence)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Botany (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
HK33695A 1987-04-02 1995-03-09 Leukaemia inhibitory factor HK33695A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
AUPI120987 1987-04-02
AUPI331787 1987-07-24
AUPI490387 1987-10-15
AUPI600587 1987-12-21

Publications (1)

Publication Number Publication Date
HK33695A true HK33695A (en) 1995-03-17

Family

ID=27424196

Family Applications (1)

Application Number Title Priority Date Filing Date
HK33695A HK33695A (en) 1987-04-02 1995-03-09 Leukaemia inhibitory factor

Country Status (15)

Country Link
US (5) US5187077A (pt)
EP (1) EP0285448B1 (pt)
JP (2) JP2682858B2 (pt)
KR (1) KR0121324B1 (pt)
CA (1) CA1341581C (pt)
DE (1) DE3888379T2 (pt)
DK (1) DK174970B1 (pt)
ES (1) ES2061643T3 (pt)
FI (1) FI113372B (pt)
HK (1) HK33695A (pt)
IL (1) IL85961A (pt)
NO (1) NO178265C (pt)
PT (1) PT87133B (pt)
SG (1) SG11795G (pt)
WO (1) WO1988007548A1 (pt)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT87133B (pt) * 1987-04-02 1992-07-31 Amrad Corp Ltd Metodo de purificacao do factor inibidor da leucemia (lif) e de composicoes farmaceuticas contendo polipeptidos com actividade do lif
CA1341469C (en) * 1988-08-04 2004-12-28 Robert Lindsay Williams In vitro propagation of embryonic stem cells
US20030032178A1 (en) * 1988-08-04 2003-02-13 Williams Robert Lindsay In vitro propagation of embryonic stem cells
WO1990002183A1 (en) * 1988-08-18 1990-03-08 Genetics Institute, Inc. Production of a novel lymphokine exhibiting differentiation inhibitory activity
US5284756A (en) * 1988-10-11 1994-02-08 Lynn Grinna Heterodimeric osteogenic factor
WO1990009442A1 (en) * 1989-02-08 1990-08-23 Uab Research Foundation Antiproliferation factor
HK1003475A1 (en) * 1989-11-24 1998-10-30 Monash University Proliferative action of leukaemia inhibitory factor on satellite cells
HK1002697A1 (en) * 1990-03-20 1998-09-11 Amrad Corporation Limited A method for regulating neuron development and maintenance
IL97779A (en) * 1990-04-10 2000-01-31 Genentech Inc Compositions for cytoprotection against radiation and chemotherapy injury or risk thereof
US5595887A (en) * 1990-07-16 1997-01-21 Bionebraska, Inc. Purification directed cloning of peptides using carbonic anhydrase as the affinity binding segment
KR940702380A (ko) * 1991-12-24 1994-08-20 스튜와트 슈트 종양 및 육종의 치료 방법(A Method for the treatment of Tumours and Sarcomas)
US5916871A (en) * 1992-04-27 1999-06-29 Kansas State University Research Foundation Inhibitory factor
JPH07508733A (ja) * 1992-07-01 1995-09-28 アムラド・コーポレイション・リミテッド 白血病抑制因子結合蛋白
EP0746569A4 (en) * 1993-02-03 1999-03-24 Amrad Corp Ltd DETERMINANT FOR FIXING THE RECEPTOR FROM THE LEUKEMIA INHIBITION FACTOR
US6849427B1 (en) * 1993-03-12 2005-02-01 Immulogic Pharmaceutical Corp. Nucleic acids encoding a house dust mite allergen, Der p VII, and uses therefor
US5849991A (en) * 1994-01-27 1998-12-15 Bresatch Limited Mice homozygous for an inactivated α 1,3-galactosyl transferase gene
WO1995020661A1 (en) * 1994-01-27 1995-08-03 Bresatec Ltd. Materials and methods for management of hyperacute rejection in human xenotransplantation
US6184370B1 (en) * 1994-02-03 2001-02-06 Amrad Corporation Limited Receptor-binding determinant from leukaemia inhibitory factor
US5824838A (en) * 1996-05-09 1998-10-20 Cedars-Sinai Medical Center Transgenic mouse model for pituitary disorders associated with LIF overexpression and/or GH underexpression, and its use for testing therapeutic drugs for the conditions
WO1998004587A1 (en) * 1996-07-25 1998-02-05 New York University POLYPEPTIDE COFACTORS THAT MEDIATE α-TUBULIN AND β-TUBULIN FOLDING
US6156729A (en) 1997-10-15 2000-12-05 California Institute Of Technology Leukemia inhibitory factor for use in modulating inflammation and pain
AUPP053197A0 (en) * 1997-11-26 1997-12-18 Amrad Operations Pty. Limited Compositions
CA2333307A1 (en) 1998-07-06 2000-01-13 The Government Of The United States Of America As Represented By The Sec Retary, Department Of Health And Human Services Compositions and methods for in vitro fertilization
US20040234539A1 (en) * 1999-11-03 2004-11-25 Powderject Research Limited Nucleic acid vaccine compositions having a mammalian cd80/cd86 gene promoter driving antigen expression
CA2412361C (en) * 2000-06-14 2011-08-23 Vistagen, Inc. Toxicity typing using liver stem cells
US6894024B2 (en) 2000-10-20 2005-05-17 Amylin Pharmaceuticals, Inc. Treatment of hibernating myocardium and diabetic cardiomyopathy with a GLP-1 peptide
US7604807B2 (en) * 2000-12-01 2009-10-20 Auburn University Use of pullulan to isolate and preserve biological material
WO2002059278A2 (en) * 2001-01-24 2002-08-01 The Government Of The United States Of America, As Represented By The Secretary Of Department Of Health & Human Services Differentiation of stem cells to pancreatic endocrine cells
US20030211605A1 (en) * 2001-05-01 2003-11-13 Lee Sang-Hun Derivation of midbrain dopaminergic neurons from embryonic stem cells
EP1435779A4 (en) * 2001-09-24 2005-06-01 Sangamo Biosciences Inc MODULATION OF STEM CELLS USING ZINC FINGER PROTEINS (ZFP)
GB0220145D0 (en) * 2002-08-30 2002-10-09 Thromb X Nv Novel compositions for the in vitro derivation and culture of embryonic stem (ES) cell lines with germline transmission capability
ATE501167T1 (de) 2001-12-21 2011-03-15 Thrombogenics Nv Zusammensetzungen für die in vitro herleitung und kultur embryonaler stammzellinien mit keimbahnübertragungsfähigkeit und für die kultur adulter stammzellen
WO2004112661A1 (en) * 2003-06-20 2004-12-29 Myers Thomas H Method and apparatus for strengthening the biomechanical properties of implants
FR2870739B1 (fr) * 2004-05-26 2008-05-16 Oreal Utilisation du lif en cosmetique et en dermatologie
FR2870854B1 (fr) * 2004-05-26 2010-12-31 Oreal Utilisation du lif en ingenierie cellulaire et tissulaire
US20050277124A1 (en) * 2004-06-10 2005-12-15 White Steven M Cardiac conduction system cells and uses thereof
MX2008016429A (es) * 2006-06-20 2009-03-20 Genzyme Corp Medios de suero y sus usos para expansion de condrocitos.
JPWO2011125948A1 (ja) 2010-04-02 2013-07-11 独立行政法人理化学研究所 Ｅｓ細胞の製造方法
KR101434739B1 (ko) * 2012-08-23 2014-09-01 울산대학교 산학협력단 인간 ＰＤＩｂ´ａ´태그를 이용한 생물학적 활성을 가진 인간 ＬＩＦ 재조합 단백질의 대장균 내 발현 및 정제방법
WO2014130706A1 (en) 2013-02-20 2014-08-28 Regeneron Pharmaceuticals, Inc. Genetic modification of rats
SMT201800671T1 (it) 2013-04-16 2019-01-11 Regeneron Pharma Modificazione mirata del genoma di ratto
WO2019169371A1 (en) * 2018-03-02 2019-09-06 University Of Florida Research Foundation, Incorporated Drug stabilized therapeutic transgenes delivered by adeno-associated virus expression

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4578355A (en) * 1983-01-12 1986-03-25 The United States Of America As Represented By The Department Of Health And Human Services Plasmid cloning vector pAS1
JPS60105621A (ja) * 1983-11-14 1985-06-11 Agency Of Ind Science & Technol 細胞の分化誘導作用を有する生理活性物質およびその製法
US4616079A (en) * 1984-08-24 1986-10-07 Imreg, Inc. Immunoamplifiers and processes for the extraction thereof
US5104650A (en) * 1985-02-05 1992-04-14 Cetus Corporation Uses of recombinant colony stimulating factor-1
DE3545568A1 (de) * 1985-12-21 1987-07-16 Hoechst Ag Gm-csf-protein, seine derivate, herstellung solcher proteine und ihre verwendung
JPS62223126A (ja) * 1986-03-25 1987-10-01 Sankyo Co Ltd 血液幹細胞成長因子
PT87133B (pt) * 1987-04-02 1992-07-31 Amrad Corp Ltd Metodo de purificacao do factor inibidor da leucemia (lif) e de composicoes farmaceuticas contendo polipeptidos com actividade do lif
JPS6448197A (en) * 1987-08-19 1989-02-22 Sanden Corp Goods takeoff port unit for vending machine
JPH01148197A (ja) * 1987-12-04 1989-06-09 Green Cross Corp:The 腫瘍細胞障害因子

Also Published As

Publication number Publication date
FI894613L (fi) 1989-09-29
US6261548B1 (en) 2001-07-17
NO178265C (no) 1996-02-21
US5750654A (en) 1998-05-12
KR0121324B1 (ko) 1997-11-28
NO885339L (no) 1989-02-01
CA1341581C (en) 2008-09-30
EP0285448B1 (en) 1994-03-16
US5443825A (en) 1995-08-22
PT87133A (pt) 1988-04-01
NO178265B (no) 1995-11-13
SG11795G (en) 1995-06-16
DK483189A (da) 1989-12-04
JP2682858B2 (ja) 1997-11-26
DE3888379D1 (de) 1994-04-21
EP0285448A3 (en) 1990-08-29
FI894613A0 (fi) 1989-09-29
PT87133B (pt) 1992-07-31
DK174970B1 (da) 2004-04-05
JPH07138292A (ja) 1995-05-30
DK483189D0 (da) 1989-10-02
DE3888379T2 (de) 1994-07-28
IL85961A (en) 1997-03-18
ES2061643T3 (es) 1994-12-16
EP0285448A2 (en) 1988-10-05
WO1988007548A1 (en) 1988-10-06
US5427925A (en) 1995-06-27
KR890700610A (ko) 1989-04-26
JPH01502985A (ja) 1989-10-12
US5187077A (en) 1993-02-16
NO885339D0 (no) 1988-11-30
FI113372B (fi) 2004-04-15
JP2721123B2 (ja) 1998-03-04

Similar Documents

Publication Publication Date Title
EP0285448B1 (en) Leukaemia inhibitory factor
JP3276933B2 (ja) エリスロポエチン活性を有する糖蛋白質の製造方法
EP0177568B1 (en) Recombinant dna molecules
JP2740417B2 (ja) ヒト神経成長因子の遺伝子組換えによる調製法
JP2553829B2 (ja) 組換えコロニー刺激因子−１
JPS61501627A (ja) ヒトエリスロポエチンをコードするｄｎａ
CZ291515B6 (cs) Izolovaná biologicky aktivní erytropoietinová izoforma, způsob její přípravy a farmaceutická kompozice na její bázi
AU8735991A (en) Hybrid growth factors
JPH04506342A (ja) 非グリコシル化ヒトインターロイキン―３類似蛋白質
EP0357067A2 (en) Recombinant natural killer cell activator
AU609128B2 (en) Leukaemia-inhibitory factor
JPH04500508A (ja) 非グリコシル化　ヒト　インターロイキン―３　組成物
JPS6363199B2 (pt)
EP0406402A1 (en) Cloning and expression of a variant gene of platelet factor 4 and compositions thereof to modulate immune responses
HU197939B (en) Process for producing deoxyribonucleic acid, or its precursor, determining human growth hormone releasing factor
US20030004098A1 (en) Leukaemia inhibitory factor
KR0121322B1 (ko) 백혈병 억제 인자 제조를 위한 재조합 dna 분자 및 숙주 세포
NZ224105A (en) Leukaemia inhibitory factor
JP3023467B2 (ja) ヒトベイシジンｉ遺伝子
CA1341625C (en) Recombinant mammalian gm-csf, dna encoding mammalian gm-scf and methods of use thereof
NO179210B (no) Fremgangsmåte for fremstilling av et LIF polypeptid, rekombinant DNA molekyl som koder for LIF polypeptidet samt vertscelle for å uttrykke dette
HU207342B (en) Process for producing human or mouceleukemie inhibitor factor /lif/ and pharmaceutical compositions of lif activity and process for purifying lif after or without glycozilation
HU204889B (en) Process for producing erythropoietin
JPH08301898A (ja) 新規なポリペプチド、その製造方法、そのポリペプチドをコードするｄｎａ、そのｄｎａからなるベクター、そのベクターで形質転換された宿主細胞、そのポリペプチドの抗体、およびそのペプチドまたは抗体を含有する薬学的組成物

Legal Events

Date Code Title Description
PF Patent in force
PE Patent expired

Effective date: 20080330